Archives: Speakers

With over 35 years of clinical research experience, Peter brings medical, scientific, and business insights into oncology and hematology drug development. His understanding of the clinical development – ranging from feasibility assessments, medical monitoring oversight, regulatory strategy, and patient safety provide him with insights for our conversation on how emerging immunotherapy combinations and novel approaches are influencing global clinical research.

Peter holds an MD and PhD from Ludwig-Maximilians-Universität München.

Adam brings nearly 30 years of experience and a strong record of building high-performing, global teams that drive clinical programs for regulatory approval and commercialization of therapies. Adam’s teams also bring an adeptness in molecule-to-market strategies and operational excellence. Adam ensures our ability to provide development strategies while delivering exceptional experiences for our clients conducting oncology, hematology and cell and gene therapy studies.

Adam holds Master of Science degrees in Biology and Clinical Psychology from the University of Washington and an MBA from Boise State University

Tariq is a Lead Clinic Trial Liaison at Regeneron responsible for expanding the clinical trial footprint in the region, providing key scientific insights and overseeing the successful delivery of oncology trials. With over 15 years of Oncology research experience, his leadership and strategic insight have fostered strong collaborations with the NHS, Private Hospitals, and research bodies such as the NIHR and Cancer Trials Office (Ireland).  These partnerships have driven impactful initiatives, with a view to significantly advancing oncology clinical research across UK and Ireland.